Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy

Brain and Development

Volumn 39, Issue 4, 2017, Pages 345-348

  Dilena, Robertino ^a   Striano, Pasquale ^b   Gennaro, Elena ^c   Bassi, Laura ^d   Olivotto, Sara ^a   Tadini, Laura ^a   Mosca, Fabio ^d   Barbieri, Sergio ^a   Zara, Federico ^b   Fumagalli, Monica ^d  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Carbamazepine; Early infantile epileptic encephalopathy; Phenytoin; SCN2A; Sodium channel blockers

Indexed keywords

CARBAMAZEPINE; LEVETIRACETAM; PHENOBARBITAL; PHENYTOIN; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; SODIUM CHANNEL NAV1.2; ANTICONVULSIVE AGENT; SCN2A PROTEIN, HUMAN; SODIUM CHANNEL BLOCKING AGENT;

ANTICONVULSANT THERAPY; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; EEG ABNORMALITY; ELECTROENCEPHALOGRAPHY; FOCAL EPILEPSY; GENE MUTATION; HETEROZYGOSITY; HUMAN; LENNOX GASTAUT SYNDROME; MALE; MONOTHERAPY; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; SPIKE WAVE; TONIC CLONIC SEIZURE; TREATMENT RESPONSE; BRAIN; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG EFFECTS; GENETICS; PATHOPHYSIOLOGY; SPASMS, INFANTILE; TREATMENT OUTCOME;

ANTICONVULSANTS; BRAIN; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFANT, NEWBORN; MALE; NAV1.2 VOLTAGE-GATED SODIUM CHANNEL; PHENYTOIN; SODIUM CHANNEL BLOCKERS; SPASMS, INFANTILE; TREATMENT OUTCOME;

EID: 85006929901     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2016.10.015     Document Type: Article

References (6)

1. [1] Ogiwara, I., Ito, K., Sawaishi, Y., Osaka, H., Mazaki, E., Inoue, I., et al. De novo mutations of voltage-gated sodium channel alpha II gene SCN2A in intractable epilepsies. Neurology 73 (2009), 1046–1053.
2. [2] Liao, Y., Anttonen, A.K., Liukkonen, E., Gaily, E., Maljevic, S., Schubert, S., et al. SCN2A mutation associated with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain. Neurology 75 (2010), 1454–1458.
3. [3] Howell, K.B., McMahon, J.M., Carvill, G.L., Tambunan, D., Mackay, M.T., Rodriguez-Casero, V., et al. SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures. Neurology 85 (2015), 958–966.
4. [4] Weckhuysen, S., Ivanovic, V., Hendrickx, R., Van Coster, R., Hjalgrim, H., Møller, R.S., et al. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology 81 (2013), 1697–1703.
5. [5] Dilena, R., Striano, P., Traverso, M., Viri, M., Cristofori, G., Tadini, L., et al. Dramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation. Brain Dev 38 (2016), 128–131.
6. [6] Striano, P., Vari, M.S., Mazzocchetti, C., Verrotti, A., Zara, F., Management of genetic epilepsies: from empirical treatment to precision medicine. Pharmacol Res 107 (2016), 426–429.